Implanon: A Review of the Literature With Recommendations for Clinical Management

Authors

  • Kate Adams WHNP-C, ANP-C, MSN,

    Corresponding authorSearch for more papers by this author
    • Kate Adams, WHNP-C, ANP-C, MSN, is a May 2008 graduate of the Yale School of Nursing, New Haven, CT. She is dually certified as a WHNP and ANP.

  • Margaret W. Beal CNM, PhD

    Search for more papers by this author
    • Margaret W. Beal, CNM, PhD, is a Clinical Professor at the Massachusetts General Hospital Institute of Health Professions in Boston, Massachusetts. She is past Chair of the ACNM Division of Education and Practiced with Planned Parenthood of Connecticut at the time this article was written.


Kate Adams, WHNP-C, ANP-C, MSN. E-mail: kate.adams@aya.yale.edu

Abstract

Implanon is a new implantable, progestin-only contraceptive which was approved in the United States in July 2006. Implanon is comprised of a single ethylene vinylacetate copolymer rod that is 4 cm long and 2 mm in diameter. It is inserted subdermally in the groove between the biceps and triceps of the nondominant arm. A literature review was conducted and side effects are discussed. Implanon offers promise as a high-efficacy, long-term contraceptive and can enhance the contraceptive options offered by the women's health care providers. Clinical trial data indicate that the device is both safe and effective.

Ancillary